儿茶素在家兔体内的药物动力学及生物利用度研究

对家兔单剂量静注和灌服儿茶素 (Catechin) 2 5mg/kg体重各 5只。用高效液相色谱法测定其血药浓度。房室模型分析表明静注给药后的药时数据符合无吸收二室开放模型 ,主要动力学参数为 :t1 / 2α=( 0 .1 5± 0 .0 1 )h ,t1 / 2 β=( 0 .5 8± 0 .0 2 )h ,Vc=( 1 .41± 0 .0 8)L ,Vβ=( 2 .97±0 .1 1 )L ,ClB=( 3.5 3± 0 .1 0 )L/h ,AUC =( 1 6.95± 1 .5 2 )mg/(L·h)。灌服儿茶素的药时数据符合一级吸收一室开放模型 ,主要药物动力学参数为 :t1 / 2Ka=( 0 .39± 0 .0 6)h ,t1 / 2Ke=( 0 .79±0 .1 1 )h ,tmax=( 0 .78± 0 .1 1 )h ,Cmax=( 3.35± 0 .1 6)mg/L ,AUC =( 7.45± 0 .94)mg/(L·h) ,F =( 4 4.1 8± 3.5 9) %。儿茶素在健康家兔体内的药动学特征是 :吸收迅速 ,达峰时间短 ,消除快 ,半衰期短 ,表观分布容积较大 ,口服摄入吸收不完全     

儿茶素在家兔体内的生物利用度及药物动力学研究

选健康家兔 ,单剂量静注和灌服儿茶素 (Catechin) 2 5 mg/ kg,用高效液相色谱法测定其血药浓度 ,3P87计算机程序处理所得血药浓度—时间数据。结果健康家兔静注给药的药时数据符合无吸收二室开放模型 ,主要动力学参数为 :t1 /2α(0 .15± 0 .0 1) h,t1 /2β(0 .5 8± 0 .0 2 ) h,Vc (1.4 1± 0 .0 8) l,Vβ(2 .97± 0 .11) l,Cl B(3.5 3±0 .10 ) l/ h,AU C(16 .95± 1.5 2 ) mg/ (l· h) ,K1 0 (2 .5 2± 0 .2 0 ) h- 1 ,K2 1 (2 .2 5± 0 .15 ) h- 1 ,K1 2 (1.17± 0 .15 )h- 1 。健康家兔灌服儿茶素的药时数据符合一级吸收一室开放模型 ,主要药物动力学参数为 :t1 /2 ka(0 .39± 0 .0 6 )h,t1 /2 ke(0 .79± 0 .11) h,tmax(0 .78± 0 .11) h,Cmax(3.35± 0 .16 ) mg/ l,AU C (7.4 5± 0 .94 ) m g/ (l· h) ,F (6 4±7.0 0 ) %。儿茶素在健康家兔体内的药动学特征是 :吸收迅速 ,达峰时间短 ,消除快 ,半衰期短 ,表观分布容积较大 ,口服摄入吸收不完全     

诺氟沙星在鲤鱼体内的药代动力学

按 10 m g/ kg的剂量给鲤鱼肌注、口服诺氟沙星 ,用高效液相色谱法检测用药后不同时间血浆中药物的质量浓度 ,然后用 90 0 0 3P87实用药代动力学软件处理药时数据。结果 ,肌注和口服诺氟沙星在鲤鱼体内的药时数据均符合开放性二室模型。主要药代动力学参数 ,肌注 :t1/2α( 0 .12 79± 0 .0 130 ) h,t1/2β( 3.4 0 32±0 .5873) h,t1/2 ka( 0 .0 0 6 7± 0 .0 0 0 8) h,AU C ( 2 4 .94 81± 6 .314 6 )μg/ ( m L· h) ,CLS( 0 .4 0 0 8± 0 .10 35)mg/ ( kg· h) ,Tpeak( 0 .0 32 2± 0 .0 0 35) h,Cmax( 16 .8992± 4 .372 6 ) mg/ L;口服 :t1/2α( 3.4 0 71± 1.0 6 98) h,t1/2β( 77.12 39± 2 1.3875) h,t1/2 ka( 0 .14 91± 0 .0 130 ) h,K2 1( 0 .0 4 19± 0 .0 0 38) h- 1,K10 ( 0 .0 4 36±0 .0 0 2 1) h- 1,K12 ( 0 .12 70± 0 .0 30 1) h- 1,AU C ( 150 .6 0 2 9± 35.4 2 78)μg/ ( m L· h) ,CLS( 0 .0 6 6 4±0 .0 0 2 1) m g/ ( kg· h) ,Tpeak( 0 .730 0± 0 .0 10 2 ) h,Cmax( 5.7998± 1.36 75) m g/ L。肌注与内服的主要药代动力学参数差异显著 ( P <0 .0 1)。     

仔猪脾虚状态下单剂量口服左旋氧氟沙星的药动学研究

10头健康仔猪随机均分为健康组、脾虚组 ,按 2 0mg/kg的剂量进行内服左旋氧氟沙星的药动学研究。高效液相色谱法测定血浆中药物浓度 ,3P97药代动力学程序处理药时数据。健康组和脾虚组药动学数据适合一级吸收一室模型。健康组主要药动学数据为 :吸收半衰期 (t1 / 2ka)(0 42± 0 0 8)h ,消除半衰期 (t1 / 2ke) (7 62± 0 38)h ,达峰时间 (tmax) (1 85± 0 2 5)h ,达峰浓度 (Cmax) (6 99± 0 92 )mg/L ,药时曲线下面积 (AUC) (90 7± 1 0 0 7)mg·L- 1 ·h ,表观分布容积 (V/ F(s) ) (2 45± 0 2 8)L·kg,平均滞留时间 (MRT) (1 1 92± 0 94)h。脾虚组 :t1 / 2ka(1 1 7± 0 38)h ,t1 / 2ke (9 0 2± 1 1 8)h ,tmax (3 93± 1 0 5)h ,Cmax (4 2 8± 1 45)mg/L ,AUC (72 2 1± 1 6 0 7)mg·L- 1 ·h ,V/ F(s) (3 95±1 2 8)L·kg,MRT (1 3 74± 1 2 1 )h。结果表明 :仔猪脾虚状态下明显影响左旋氧氟沙星内服给药的药动学特征     

麻保沙星(marbofloxacin)在鸡体内的生物利用度及药物动力学

选用 36只 5 1～ 6 0日龄健康岭南黄鸡 ,随机均分为 3组 ,对静注、肌注及内服麻保沙星 (2 .5 mg/ kg)的生物利用度和药物动力学进行了研究。用三氯甲烷提取血浆中的药物 ,反相高效液相色谱法测定血浆中麻保沙星的浓度 ,MCPKP计算机程序处理所得到的血药浓度 -时间数据。静注给药的药时数据适合三室开放模型 ,主要药动学参数分别为 :t1 /2π(0 .19± 0 .0 3) h;t1 /2α(2 .0 7± 0 .2 7) h;t1 /2β(6 .5 2± 0 .6 9) h;V1 (0 .48± 0 .0 3) L / kg;Vd(area) (2 .0 6± 0 .39)L/ kg;Vd(ss) (1.0 5± 0 .0 6 ) L/ kg;Cl B(0 .19± 0 .0 2 ) L/ (kg· h) ;AUC(13.95± 1.0 7) mg· kg- 1 · h。肌注给药的药时数据适合一级吸收二室开放模型 ,主要药动学参数分别为 :t1 /2 Ka(0 .5 4± 0 .0 5 ) h;t1 /2α(2 .33± 0 .2 0 ) h;t1 /2β(6 .2 7± 0 .46 )h;tmax(1.5 7± 0 .0 9) h;Cmax(1.88± 0 .0 5 ) m g/ L ;AUC(13.18± 0 .6 7) mg· kg- 1 · h;F(94.45± 4.80 ) %。内服给药的药时数据适合一级吸收二室开放模型 ,主要药动学参数分别为 :t1 /2 Ka(0 .42± 0 .0 6 ) h;t1 /2α(2 .31± 0 .2 5 ) h;t1 /2β(6 .48±0 .6 6 ) h;tmax(1.35± 0 .12 ) h;Cmax(1.83± 0 .18) mg/ L;AUC(13.5 5± 0 .6 7) mg· k     

肉仔鸡静注和内服环丙沙星(ciprofloxacin)的药物动力学

16只健康 AA肉仔鸡 ,随机分成 2组 ,每组 8只 ,按 10 mg/ kg剂量分别进行静注和内服单剂量环丙沙星药动学试验。血浆中药物浓度用高效液相色谱法测定 ,血药浓度 -时间数据用 MCPKP药动学计算机程序处理。结果表明 ,静注给药后的药时数据符合无吸收二室开放模型 ,主要动力学参数分别为 :t1 /2α为 (0 .2 34± 0 .0 49) h,t1 /2β为 (10 .118±0 .2 71) h,VB为 (1.374± 0 .12 4) L/ kg,CLB为 (0 .0 94± 0 .0 0 9) L· kg- 1 · h- 1 ,AUC为 (10 7.0 6 8± 10 .6 40 ) mg· L- 1· h。内服给药后的药时数据符合一级吸收一室开放模型 ,主要动力学参数分别为 :t1 /2 kα为 (0 .114± 0 .0 0 8) h,t1 /2 k为(7.784± 0 .5 14) h,Tp 为 (0 .70 2± 0 .0 31) h,Cmax为 (5 .736± 0 .5 15 ) m g/ L,AUC为 (6 8.6 2 2± 8.147) mg· L- 1· h,F为 (6 4.0 92± 7.6 10 ) %。肉仔鸡静注环丙沙星在其体内消除较慢 ,分布广泛 ;内服给药吸收迅速 ,消除较静注给药快。     

沙拉沙星在猪体内的药动学研究

7头健康杂种猪 ,按照随机拉丁方设计 ,进行静注、肌注及内服沙拉沙星 (5mg/kg)的药动学研究。血浆样品经甲醇沉淀血浆蛋白 ,高速离心 ,用反相高效液相色谱法测定猪血浆中沙拉沙星的浓度 ,MCPKP计算机程序处理血浆药物浓度 时间数据。健康猪静注给药的药时数据适合二室开放模型 ,主要药物动力学参数为t1/ 2α0 88±0 2 8h ;t1/ 2 β3 0 6± 0 5 0h ;V11 36± 0 2 4L/kg ;Vd(area) 2 5 0± 0 42L/kg ;ClB0 5 7± 0 0 7L·kg-1·h-1;AUC8 90±1 0 3mg·L-1·h。健康猪肌注给药的药时数据适合一级吸收一室模型 ,主要药物动力学参数为 :t1/ 2ka0 2 5± 0 18h ;t1/ 2ke3 5 3± 1 0 1h ;tmax0 94± 0 49h ;Cmax1 30± 0 37μg/ml;AUC 7 6 6± 1 38mg·L-1·h ;F86 48%± 15 15 %。健康猪内服给药的药时数据适合一级吸收一室模型 ,主要药物动力学参数为 :t1/ 2ka0 5 1± 0 2 9h ;t1/ 2ke6 72± 2 78h ;tmax2 45± 0 89h ;Cmax0 36± 0 2 1μg/ml;AUC　 4 5 4± 1 0 6mg·L-1·h ;F5 1 99%± 14 6 7%。沙拉沙星在健康猪体内的主要药动学特征为 :吸收迅速 ,达峰时间短 ,表观分布容积大。肌注给药吸收完全 ;内服给药吸收不完全 ,消除缓慢。     

恩诺沙星混悬液在猪体内的药动学及生物利用度

本文比较了恩诺沙星混悬液和恩诺沙星溶液在猪体内的药动学特征和生物利用度。选用 7头健康猪按拉丁方设计进行静注、肌注恩诺沙星溶液和肌注恩诺沙星混悬液在猪体内的药物动力学研究。 3种给药方法的剂量均为 10mg/kg。猪静注给药的药时数据符合二室开放模型 ,主要药动学参数为 :t1/ 2α0 6 4± 0 15h ,t1/ 2 β9 0 6± 2 47h ,Vd(area) 4 40± 0 88L/kg ,ClB0 35± 0 0 6L·kg-1·h-1,AUC2 9 85± 4 11L·kg-1·h。猪肌注恩诺沙星溶液和恩诺沙星混悬液的药时数据符合一级吸收一室模型 ,其主要药动学参数分别为t1/ 2ka0 2 4± 0 10h和 1 2 5± 1 0 9h(P <0 0 5 ) ;t1/ 2ke8 90± 2 0 2h和 18 95± 4 5 5h(P <0 0 1) ;Tmax1 2 5± 0 41h和 5 14± 2 95h(P <0 0 1) ;Cmax1 5 4± 0 2 5 μg/ml和 0 87± 0 2 1μg/ml;AUC2 1 49± 4 94mg·L-1·h和 2 8 97± 10 80mg·L-1·h ;F72 0 %±17 4%和 97 7%± 35 0 %。比较肌注恩诺沙星混悬液和恩诺沙星溶液的主要药动学参数 ,二者有显著差异 ,前者的t1/ 2ka、Tmax、t1/ 2ke和Cmax分别为后者的 5 2、4 1、2 1和 0 6倍。这些差异说明恩诺沙星混悬液肌注后吸收缓慢 ,消除半衰期延长 ,临床应用 48h给药 1次仍能维持对常见病原菌的有效血药     

克蚕菌的药物动力学研究

采用微生物法测定 5龄健康家蚕食下克蚕菌后的经时过程血药浓度。用药物动力学软件结合EXCEL程序拟和计算 ,克蚕菌在蚕体内的血药浓度—时间曲线符合一级吸收动力学和单室模型特征。其血药浓度随时间变化的单室模型关系式为C =16 .6 2 87(e-0 119t-e-0 742t) ,实测血药浓度—时间曲线与理论血药浓度—时间曲线的相关系数R2 =0 .96 33。求得克蚕菌的药物动力学参数分别为 :ka=(0 .74 2± 0 .12 3) /h ;k =(0 .119± 0 .0 0 3) /h ;t1/ 2 (a)=(0 95 8± 0 180 )h ;t1/ 2 =(5 82 1± 0 15 3)h ;Cmax=(9 70 7± 0 16 3) μg/mL ;Tmax=(2 .971± 0 .32 2 )h ;VD=(0 .5 4 3± 0 .0 2 5 )L ;CL =(0 .0 6 5± 0 .0 0 1)L/h ;AUC =(117.5 0 3± 3.30 6 )h·(μg/mL)。     

替米考星静脉及皮下注射后在绵羊体内的药代动力学研究

健康成年杂交绵羊静脉和皮下注射替米考星注射液后,用反相高效液相色谱法测定不同时间点血清中的药物浓度。采用3p97药代动力学程序软件处理数据,替米考星两种给药途径的药 时数据均符合二室开放模型静脉注射给药(5 mg/kg bw)的主要药代动力学参数: t1/2a 为 0. 611±0. 017 h、t1/2β为 23. 215±0. 459 h、AUC为11 815±0.396(μg/mL)·h、CL(s)为 0.424±0.014 L/(kg·h)。替米考星皮下注射主要药代动力学参数: 1mg/kg bw剂量组 t1/2a 为 1 751±0 557 h、t1/2β为 22 896±2 747 h、t1/2Ka 为 0. 100±0. 025 h、AUC 为 25. 828±1 479 (μg/mL)·h、CL(s)为0.393±0.017 L/(kg·h),Tmax为0.500±0.065 h,Cmax为1.424±0.156μg/mL、F为109.28%±6.25%。30 mg/kg bw剂量组 t1/2a为1.342±0.244 h、t1/2β为 20.052±1.236 h、t1/2Ka为 0.086±0.015h、AUC为57 575±6.760 (μg/mL)·h、CL(s)为0.527±0.068 L/(kg·h)、Tmax为0.437±0.039 h、Cmax为 3.343±0 512μg/mL、F为81.22%±9.54%。结果表明,绵羊静脉和皮下注射替米考星体内分布广,消除缓慢;皮下注射后在体内吸收迅速,达峰快,生物利用度高。     

Scrapie in goats in Cyprus

Ovine scrapie was first recorded in Cyprus in 1985. Subsequently four dairy goats kept in two mixed flocks with affected sheep developed characteristic clinical signs similar to those seen in sheep. Fifteen goats from the two flocks were examined histologically and neurological lesions consistent with a diagnosis of scrapie were found in the four animals and in three others which had subsequently developed early neurological signs. These lesions were similar to those of naturally-affected sheep although neuronal degeneration and vacuolation were more severe in some cases.     

Heartworm in dogs in Canada in 1984

In late December 1984, 1853 institutional veterinarians and small and mixed animal clinics across Canada were sent a questionnaire in order to assess the status of Dirofilaria immitis in Canada in 1984 and 35% of them responded. Veterinarians reported that 97,794 dogs were blood-tested to check for microfilariae and 1417 dogs (1.45% of those tested) were found with heartworm. Another 34 dogs were amicrofilaremic, but were diagnosed as having heartworm disease, to give the total number diagnosed in 1984 as 1451 (1.48%). Heartworm was reported from all provinces except Prince Edward Island and Newfoundland but most (1310) of the cases were in Ontario. In Quebec, 126 cases were reported mostly from west of Montreal.

Heartworm was found most frequently in companion dogs over three years of age maintained mainly outdoors in rural areas. About 27% of the cases were observed with clinical signs of heartworm disease and 72% had a history of not having left Canada. Southwestern Ontario continued to be the primary focus of the infection.

     

Heartworm in dogs in Canada in 1983

In late December 1983, 2 800 veterinarians across Canada were sent a questionnaire in order to assess the status of heartworm disease in Canada in 1983 and 26% of them responded. Veterinarians reported that 59 504 dogs were blood-tested to check for microfilariae and 771 dogs (1.30% of those tested) were found with Dirofilaria immitis. Heartworm disease was diagnosed in all provinces except New Brunswick and Newfoundland but most (733) of the cases were in Ontario.

Heartworm disease was found most frequently in companion dogs over three years of age maintained mainly outdoors in rural areas. About 31% of the cases were observed with clinical signs of heartworm disease and 64% had a history of not having left Canada. Southwestern Ontario continues to be the focus of the infection and most of the dogs there had not left the province previously.

     

Heartworm in dogs in Canada in 1991

In late November 1991, 1883 clinics in Canada were sent a questionnaire to assess the status of Dirofilaria immitis in dogs in 1991 and there was a 60.0% response. There were 344,031 dogs tested for heart-worm (HW), 627 were found infected and the prevalence of HW infection was 0.18%. There were 417 dogs with HW in Ontario, 116 in Manitoba, 38 in Quebec, 53 in British Columbia, three in Alberta, and one in Nova Scotia. In British Columbia, all of the infected dogs but one were from the Okanagan valley which, as from 1991, is a new focus of infection in Canada. Most dogs with HW had not been on preventive medication in 1990, and the prevalence among dogs tested and unprotected was 0.59%. That prevalence was considerably higher in endemic areas. Companion dogs, over three years of age and maintained primarily outdoors in rural areas, were most frequently infected. One cat was diagnosed with D. immitis and 33 dogs had Dipetalonema reconditium.     

Heartworm in dogs in Canada in 1985

In late December 1985, 1485 institutional veterinarians and small and mixed animal clinics across Canada were sent a questionnaire in order to assess the status of Dirofilaria immitis in Canada in 1985 and 44% of them responded. Veterinarians reported that 137,300 dogs were blood-tested to check for microfilariae and 1210 dogs were found with heartworm. Another 36 dogs were amicrofilaremic but diagnosed with heartworm disease to give the total number diagnosed in 1985 as 1247 (0.91%).

Heartworm was reported from all provinces except Prince Edward Island, Newfoundland and Saskatchewan but most (1126) of the cases were in Ontario. Southwestern Ontario continued to be the primary focus of the infection in Canada. From Quebec, 91 cases were reported mostly from and around Montreal. From Manitoba, 19 cases were reported from Winnipeg and surrounding areas. Heartworm was found most frequently in companion dogs over three years of age maintained mainly outdoors in rural areas. About 28% of the cases were observed with clinical signs of heartworm disease and 78% had a history of not having left Canada.

     

Heartworm in dogs in Canada in 1988

In late November 1988, 1581 small and mixed animal clinics and institutional veterinarians across Canada were sent a questionnaire in order to assess the status of Dirofilaria immitis in Canada in 1988, and 46% of them responded. Veterinarians reported that 181,577 dogs were blood-tested for heartworm disease and 367 dogs were found with D. immitis microfilariae. Another 60 dogs were amicrofilaremic but diagnosed with heartworm disease to give the total number of cases diagnosed in 1988 as 441 (0.24%).     

Heartworm in dogs in Canada in 1989

In late November 1989, 1732 clinics and institutional veterinarians were sent a questionnaire to assess the status of Dirofilaria immitis, and 51.7% responded. Of 247,716 dogs tested, 394 had D. immitis microfilariae and 51 were amicrofilaremic for a total of 445 cases and heartworm prevalence of 0.17%. Most (408) of these dogs had no preventive medication and the prevalence among dogs tested and unprotected was 1.01%. That prevalence was considerably higher in endemic areas. Thirty-seven dogs with heartworm had preventive medication. Heartworm was most frequent in companion dogs over three years of age maintained outdoors in rural areas. About 75% of the cases had never left Canada, 26% had clinical signs and 125 were not treated.

Heartworm was reported from British Columbia, Manitoba, Ontario, Quebec, Nova Scotia and Newfoundland, but 383 cases were in Ontario. South-western Ontario was the primary focus of infection. There were 33 cases in Quebec and 24 in Manitoba, mainly found in and around Metropolitan Montreal and Winnipeg respectively.